Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and Capecitabine/Radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma

Cancer

Volumn 121, Issue 5, 2015, Pages 673-680

  Sherman, William H ^a   Chu, Kyung ^b   Chabot, John ^a   Allendorf, John ^a,c   Schrope, Beth Ann ^a   Hecht, Elizabeth ^a   Jin, Brian ^a   Leung, David ^a   Remotti, Helen ^a   Addeo, Gisella ^a   Postolov, Inna ^a   Tsai, Wei ^a   Fine, Robert L ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

Capecitabine; Docetaxel; Gemcitabine; Pancreatic cancer; Radiation therapy

Indexed keywords

CAPECITABINE; DOCETAXEL; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; TAXOID;

ABSCESS; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BILE LEAKAGE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HAND FOOT SYNDROME; HEPATITIS; HUMAN; HYPOTENSION; LEUKOPENIA; LIVER ABSCESS; LIVER FAILURE; LUNG EMBOLISM; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS FISTULA; PANCREAS SURGERY; PERIPHERAL ISCHEMIA; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA VEIN OCCLUSION; SEPTIC SHOCK; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; VERY ELDERLY; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; PROCEDURES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84923416455     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29112     Document Type: Article

References (36)

1. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297:267-277.
2. Evans DB, Varadhachary GR, Crane CG, et al. Preoperative gemcitabine-based chemoradiation therapy for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26: 3496-3501.
3. Turrini O, Ychou M, Moureau-Zabotto L, et al. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: new neoadjuvant regimen was safe and provided an interesting pathologic response. Eur J Surg Oncol. 2010; 36:978-992.
4. Chang DK, Johns AJ, Merrett ND, et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol. 2009; 27:2855-2862.
5. Campbell F, Smith RA, Whelan P, et al. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection. Histopathology. 2009; 55: 277-283.
6. Mamon HJ, Niedzwiecki D, Hollis D, et al. A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma: Cancer and Leukemia Group B (CALGB) 80003. Cancer. 2011; 117:2620-2628.
7. Michael M, Price T, Ngan SY, et al. A phase I trial of capecitabine 1gemcitabine with radical radiation for locally advanced pancreatic cancer. Br J Cancer. 2009; 100:37-43.
8. Huang J, Robertson JM, Margolis J, et al. Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer. Radiother Oncol. 2011; 99:114-119.
9. Schellenberg D, Kim J, Christman, et al. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011; 8:181-188.
10. Small W Jr, Berlin J, Freedman GM, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with non-metastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008; 26:942-947.
11. Cengiz M, Zorlu F, Yalcin S, et al. Concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Med Oncol. 2007; 24:239-243.
12. Cardenes HR, Moore AM, Johnson CS, et al. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hosier Oncology Group Study. Am J Clin Oncol. 2012; 34:460-465.
13. Shibuya K, Ova N, Fuji K, et al. Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer. Am J Clin Oncol. 2011; 34:1150119.
14. Crane CH, Winter K, Regine WF, et al. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOC 0411. J Clin Oncol. 2009; 27:49-096-4102.
15. Varachachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26:3487-3495.
16. Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group Trial. J Clin Oncol. 2011; 29:4015-4112.
17. Haddock MG, Swaminathan R, Foster NR, et al. Gemcitabine, cisplatin and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group phase II study N9942. J Clin Oncol. 2007; 20:2567-2572.
18. Brade A, Brierley J, Oza A, et al. Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resectable pancreatic cancer: a phase I-II study. Int J Radiat Oncol Biol Phys. 2007; 67:1027-1036.
19. Gunnlaugsson A, Anderson H, Lind P, Glimelius B, Johnson A. Multicenter phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: the CORGI-U study. Radiother Oncol. 2010; 95:292-297.
20. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008; 19:1592-1599.
21. Cohen SJ, Dobelbower R Jr, Lipsitz S, et al. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys. 2005; 62:1345-1350.
22. Rich T, Harris J, Abrams R, et al. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-96-12. Am J Clin Oncol. 2004; 27:51-56.
23. Fine RL, Fogelman DR, Schreibman SM, et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol. 2008; 61:167-175.
24. Burris HA III, Moore MJ, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15:2403-2413.
25. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817-1825.
26. Decreux M, Mutry E, Oud-Kaci M, et al. Randomized phase II study evaluation oxaliplatin alone, oxaliplatin combined with infusion al 5-FU and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol. 2004; 15:467-473.
27. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J Clin Oncol. 2002; 20:3270-3275.
28. Scheithauer W, Schull B, Ulrich-Pur H, et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol. 2003; 14:97-104.
29. Di Costanzo F, Carlini P, Doni L, et al. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomized phase II trial of the Italian Oncology Group for Clinical Research (GOIRC). Br J Cancer. 2005; 93:185-189.
30. Bernhard J, Dietrich D, Scheithauer W, et al. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial-SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol. 2008; 26:3695-3701.
31. Von Hoff D, Ervin T, Arena F, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369:1691-1703.
32. Hosein P, Macintyre J, Mawamura et al. A retrospective study of neoad-juvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012; 12:199.
33. Faris JE, Blaszkowsky LS, McDermott S, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer center experience. Oncologist. 2013; 18:543-548.
34. Patel M, Hoffe S, Malafa M, et al. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol. 2011; 104:155-161.
35. Garcia-Manteiga J, Molina-Arcas M, Casasdo FJ, Mazo A, PastorAnglada M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCN1 in 2',2'-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res. 2003; 9:5000-5008.
36. Gouillat C, Gigot J. Pancreatic surgical complications - the case for prophylaxis. Gut. 2001; 49:29-36.